Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Within-patient, placebo-controlled trial of Juvista (avotermin) for improving appearance of existing scars
2008-004938-24Phase 2Terminated
- Sponsor
- Renovo
- Start
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of avotermin in severe cutaneous adverse reactions (SCAR), sponsored by Renovo. Primary endpoint: Improvement of scar appearance at 6 months post-treatment. Started Oct 2008; status: terminated.
02
Drugs
avotermin
03
Conditions
severe cutaneous adverse reactions (SCAR)
Beyond the preview
Go deeper on 2008-004938-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004938-24.